Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Stock analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Bradmer Pharmaceuticals in a research note issued on Tuesday, February 25th. Cantor Fitzgerald analyst B. Knoblauch expects that the company will post earnings per share of $2.74 for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. Cantor Fitzgerald also issued estimates for Bradmer Pharmaceuticals’ FY2025 earnings at $3.35 EPS.
Bradmer Pharmaceuticals Stock Performance
Read More
- Five stocks we like better than Bradmer Pharmaceuticals
- Stock Splits, Do They Really Impact Investors?
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- Dividend Capture Strategy: What You Need to Know
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
